Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jennifer French

Psychiatry Glendale, CO Doctor of Osteopathy

NPI 1801244207 CMS profile 7666467

425 S Cherry St Ste 620, Glendale, CO 80246

Open in the dashboard

General payments

$115,462

748 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer French of Glendale, CO is reported in the CMS Open Payments database as having received $115,462 across 748 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,263 202
2024 General $44,772 197
2023 General $39,539 191
2022 General $1,749 96
2021 General $937 52
2020 General $202 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer French
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jennifer French were reported at $28,263. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jennifer French Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $202 $119 $36–$372 $114
2021 $937 $143 $43–$576 $132
2022 $1,749 $153 $50–$590 $149
2023 $39,539 $170 $56–$651 $160
2024 $44,772 $179 $57–$673 $164
2025 $28,263 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $97,253 333 payments
  2. ITI, Inc. $10,963 75 payments
  3. Lundbeck LLC $1,332 67 payments
  4. Tris Pharma Inc $821 20 payments
  5. Vanda Pharmaceuticals Inc. $759 38 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $605 30 payments
  7. Otsuka America Pharmaceutical, Inc. $532 28 payments
  8. Teva Pharmaceuticals USA, Inc. $530 18 payments
  9. Alkermes, Inc. $499 25 payments
  10. Ironshore Pharmaceuticals Inc. $387 22 payments
  11. Other $1,782 92 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $84,335 59 payments
  2. Food and Beverage $14,529 644 payments
  3. Travel and Lodging $11,151 40 payments
  4. Consulting Fee $5,400 4 payments
  5. Education $47 1 payment
Products named General payments · program years 2020–2025
  1. VRAYLAR Neuroscience $80,859 244 payments
  2. VRAYLAR Neuroscience $15,843 78 payments
  3. CAPLYTA Psychiatry $10,157 33 payments
  4. REXULTI Psychiatry $1,301 65 payments
  5. CAPLYTA Psychiatry $806 42 payments
  6. Dyanavel XR $778 19 payments
  7. FANAPT $759 38 payments
  8. REXULTI Psychiatry $589 29 payments
  9. TRINTELLIX $561 28 payments
  10. LYBALVI $499 25 payments
  11. Other $4,909 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

30

Median for Psychiatry: 574

Drug cost

$1,479

Median for Psychiatry: $27,624

Branded share of claims

56.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Bupropion Xl Bupropion Hcl Brand 17 $1,347
Buspirone Hcl Generic 13 $133

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$42,901 — —
REXULTI
$394 — —
CAPLYTA
$368 — —
TRINTELLIX
$166 — —
Dyanavel XR
$151 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

748 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record